{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:36:04Z","timestamp":1770723364897,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jcjo.2015.10.004","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T23:38:11Z","timestamp":1449272291000},"page":"409-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent"],"prefix":"10.1016","volume":"50","author":[{"given":"Kamiar","family":"Mireskandari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasrin","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2015.10.004_bib1","series-title":"Pediatric Ophthalmology: Current Thought and A Practical Guide","first-page":"375","article-title":"Retinopathy of prematurity","author":"Coats","year":"2009"},{"key":"10.1016\/j.jcjo.2015.10.004_bib2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"117","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2015.10.004_bib3","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1542\/peds.2006-2162","volume":"118","author":"Erratum","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2015.10.004_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaapos.2011.07.017","article-title":"Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"15","author":"VanderVeen","year":"2011","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2015.10.004_bib5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study","volume":"115","author":"Quinn","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.10.004_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the Early Treatment for Retinopathy of Prematurity study","volume":"128","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820530701420082","article-title":"Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story","volume":"22","author":"Quiroz-Mercado","year":"2007","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.jcjo.2015.10.004_bib10","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bebacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","author":"Lalwani","year":"2008","journal-title":"Retina."},{"key":"10.1016\/j.jcjo.2015.10.004_bib12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.10.004_bib13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antioangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.10.004_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib16","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type I retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.10.004_bib17","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/IAE.0b013e3181ca146b","article-title":"Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity","volume":"30","author":"Kychenthal","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.10.004_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"Law","year":"2010","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2015.10.004_bib19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","article-title":"Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels","volume":"248","author":"Lee","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","article-title":"Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage","volume":"248","author":"Nazari","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthlamol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.10.004_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for Stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2015.10.004_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMe1100248","article-title":"Bevacizumab for retinopathy of prematurity","volume":"364","author":"Reynolds","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jcjo.2015.10.004_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) with vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib25","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"Hard","year":"2011","journal-title":"Acta Paediatrica"},{"key":"10.1016\/j.jcjo.2015.10.004_bib26","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMc1103460","article-title":"Bevacizumab for retinopathy of prematurity [letter]","volume":"364","author":"Good","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jcjo.2015.10.004_bib27","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMc1103460","article-title":"Bevacizumab for retinopathy of prematurity [letter]","volume":"364","author":"Gilbert","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jcjo.2015.10.004_bib28","first-page":"2360","article-title":"Bevacizumab for retinopathy of prematurity [letter]","volume":"364","author":"Lim","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jcjo.2015.10.004_bib29","first-page":"2360","article-title":"Bevacizumab for retinopathy of prematurity [letter]","volume":"364","author":"Gole","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jcjo.2015.10.004_bib30","first-page":"97","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"104","author":"OKeefe","year":"2011","journal-title":"Ir Med J"},{"key":"10.1016\/j.jcjo.2015.10.004_bib31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.10.004_bib32","doi-asserted-by":"crossref","unstructured":"Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98:F170-4","DOI":"10.1136\/archdischild-2011-301148"},{"key":"10.1016\/j.jcjo.2015.10.004_bib33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol. 2012;"},{"key":"10.1016\/j.jcjo.2015.10.004_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archophthalmol.2011.1802","article-title":"Significant treatment failure with intravenous bevacizumab for retinopathy of prematurity","volume":"130","author":"Patel","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3368\/aoj.60.1.9","article-title":"ROP: a cautionary tale: what we know and what we think we know","volume":"60","author":"Reynolds","year":"2010","journal-title":"Am Orthoptic J"},{"key":"10.1016\/j.jcjo.2015.10.004_bib36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00431-005-1698-8","article-title":"A literature review on off-label drug use in children","volume":"164","author":"Pandolfini","year":"2005","journal-title":"Euro J Pediatric"},{"key":"10.1016\/j.jcjo.2015.10.004_bib37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jpeds.2012.02.035","article-title":"Obesity and neglect: it\u2019s about the child","volume":"160","author":"Allen","year":"2012","journal-title":"J Pediatric"},{"key":"10.1016\/j.jcjo.2015.10.004_bib38","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archopht.119.8.1110","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib39","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity. Results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.10.004_bib40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10350-004-0892-5","article-title":"Ethical issues in innovative colorectal surgery","volume":"48","author":"Marron","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jcjo.2015.10.004_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0146-0005(98)80038-4","article-title":"Ethical dilemmas in medical innovation and research: distinguishing experimentation from practice","volume":"22","author":"Fost","year":"1998","journal-title":"Semin Perinatol"},{"issue":"suppl","key":"10.1016\/j.jcjo.2015.10.004_bib42","first-page":"5856","article-title":"Anti-VEGF agents in retinopathy of prematurity (ROP): results of a utilization survey and recommendations for the consent process","volume":"53","author":"Mireskandari","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2015.10.004_bib43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/adc.2009.180695","article-title":"Parental comprehension and satisfaction in informed consent in paediatric clinical trials: a prospective study on childhood leukaemia","volume":"95","author":"Chappuy","year":"2010","journal-title":"Arch Dis Child"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418215004196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418215004196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:04:42Z","timestamp":1757793882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418215004196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0008418215004196"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2015.10.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2015.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}